OpenAI began rolling out GPT-6 Rosalind Research (GPT-Rosalind-6 in the system card addendum), a model for life-sciences research, to a limited set of approved customers. It uses the same weights as GPT-6 Astra with no additional training; what differs is where the refusal boundaries sit for biological questions and how access is controlled. Use requires approval of both the organization and its users under the Trusted Access program, and the model is available in ChatGPT Business's Work, in Codex, and in the API as gpt-6-rosalind, but not in the Chat tab. Intended uses include target discovery, genomics and sequence analysis, protein analysis, medicinal chemistry, literature synthesis, experiment planning, and wet-lab troubleshooting. OpenAI rates its biological and chemical capability "High," below "Critical," and keeps the real-time cyber blocking inherited from Astra.
30October 2026